Improved lentivirus recovery by weak anion exchange capture
Nov
15
2022
On demand

Improved lentivirus recovery by weak anion exchange capture

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Sponsor
Improved lentivirus recovery by weak anion exchange capture

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Purification of lentiviral vector is highly challenging due to the low stability of the enveloped virus that is sensitive to low pH, high salt, temperature, and shear forces for example. Typically, LV purification is carried out using anion exchange capture chromatography, but with low recoveries. As such, improved approaches to LV recovery underpin the potential for scalable, safe cell and gene therapy manufacture. 

In this webinar you will learn more about:

  • Real world challenges in the lentiviral manufacturing workflow, with a focus on downstream processes
  • Utilizing weak anion exchange capture to optimize downstream purification efficiency and vector recovery
Lisa Marx PhD
Lisa Marx PhD
Scientist Viral Vector Applications, Cytiva

Dr. Lisa Marx is a Scientist in the Viral Vector Application group at Cytiva holding a PhD in Industrial Biotechnology. Lisa joined Cytiva in 2020, gaining experience in handling of Lentivirus, Adeno-Associated Virus, mAbs and mRNA. Her focus is on developing downstream processing and analysis of Lentivirus and thereby providing hands-on, reliable and innovative downstream solutions for gene therapy.

SPEAKERS

Lisa Marx PhD
Lisa Marx PhD
Scientist Viral Vector Applications, Cytiva

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual
27 June
in 69
Days
Register
Pure and simple: understanding LNP analytics for better mRNA-based drugs

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe
29 May
in 40
Days
Register
Empowering patient care: in-process and quality control solutions for cellular therapies

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz
23 May
in 34
Days
Register
T cells from beginning to end: optimizing leukopak and drug product cryopreservation

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity
22 May
in 33
Days
Register
Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes
21 May
in 32
Days
Register